The predictive value of serum LMTK3 and SOX4 for prognosis in patients with bladder cancer

To discuss the relationship between lemur tyrosine kinase 3 (LMTK3), sex-determining region Y-box protein 4 (SOX4) and the prognosis of bladder cancer patients. From March 2015 to March 2020, 142 patients with bladder cancer in our hospital were included as research objects, and were assigned into survival group (101 cases) and death group (41 cases) according to 5-year prognosis. Clinical characteristics of patients were collected, and ELISA was performed to discuss serum LMTK3 and SOX4. Multivariate Cox regression was performed to discuss prognostic factors. ROC curve was plotted to discuss the predictive value of these indicators for prognosis. Kaplan-Meier method was performed to analyze the relationship between indicators and the 5-year survival rate. Serum LMTK3 and SOX4 were correlated with T stage, N stage, M stage and lymphovascular invasion in patients with bladder cancer ( P < 0.05). The death group had clearly higher serum LMTK3 and SOX4 in bladder cancer patients, and the proportions of M1 stage and lymphovascular invasion than the survival group ( P < 0.05). M stage, lymphovascular invasion, LMTK3, SOX4 were all independent risk factors for death of bladder cancer patients ( P < 0.05). The AUC values of serum LMTK3 and SOX4 alone and their combination in predicting the prognosis of bladder cancer patients were 0.846, 0.801, 0.945, and the AUC of combination was higher (Z = 2.333, 2.683, P < 0.05). The 5-year survival rates of patients with high LMTK3 and SOX4 in bladder cancer were lower than those of patients with low LMTK3 and SOX4 (log rank χ 2 = 20.334, 17.223, P < 0.05). LMTK3 and SOX4 have important reference value for the prognosis evaluation of bladder cancer patients.